Viking Therapeutics posted results of an experimental drug that showed even better weight loss than the current market-leading drugs, a sign that the dominance of Ozempic and Mounjaro is far from assured.
Health insurer says it is working to restore operations after Change Healthcare breach, which affected U.S. pharmacies and military clinics and hospitals worldwide.
The bank estimates that weight-loss drugs, called GLP-1 agonists, could increase the nation's GDP by an extra 1% over the next decade, the equivalent of about $360 billion per year.